stockrow
Saturday 7 November 2026
Export GLUE’s income statement to Excel — free account
Monte Rosa Therapeutics, Inc.
GLUE Healthcare Biotechnology
Monte Rosa Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $123.7 million, up 63.5% from fiscal 2024.
- Revenue
- +325.8%
- EPS
- +109.1%
- Free cash flow
- −142.6%
Quarter to September 2026, against a year earlier
10.49
0.24
+2.34%
Follow GLUE
Alert me
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | — | 6.78 | 10.53 |
Altman Z-Score |
— | — | — | — | — | — | 0.19 | 2.89 |
P/FCF ratio |
— | — | — | — | — | — | 13.50 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | (0.12) | 1.67 |
Beneish M-Score |
— | — | — | — | — | — | — | 34.93 |
P/Operating CF |
— | — | — | — | — | — | 3.98 | (30.28) |
P/B ratio |
— | — | — | — | — | — | 2.30 | 5.59 |
Price to Tangible BV |
— | — | — | — | — | — | 2.30 | 5.59 |
EV/Sales |
— | — | — | — | — | — | 1.86 | 7.48 |
EV/EBITDA |
— | — | — | — | — | — | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | 3.35 | (40.59) |
EV/FCF |
— | — | — | — | — | — | 3.70 | (33.66) |
Quick Ratio |
— | 2.15 | 1.42 | 20.80 | 10.62 | 5.00 | 2.37 | 6.05 |
Current Ratio |
— | 2.27 | 1.49 | 20.96 | 10.79 | 5.07 | 2.40 | 6.12 |
Net Debt/EBITDA |
— | (1.23) | 1.52 | 4.89 | 2.43 | 1.70 | 5.10 | 8.22 |
Debt/Assets |
0.00% | 170.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (1.56) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.28 |
Operating CF/Net income |
— | 0.80 | 0.64 | 0.80 | 0.85 | 0.32 | (0.58) | 0.59 |
Capex/Depreciation |
— | 0.00 | (6.31) | (4.53) | (3.42) | (3.05) | (0.49) | (0.56) |
| — | 25.43% | 117.88% | (49.51%) | (35.06%) | (60.07%) | (36.15%) | (16.94%) | |
| — | (139.53%) | (118.66%) | (35.58%) | (30.62%) | (41.90%) | (19.58%) | (8.71%) | |
ROIC |
— | 0.00% | 0.00% | (3,154.52%) | (920.94%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (113.79%) | (189.45%) | (21.48%) | (39.11%) | (60.58%) | (29.08%) | (10.88%) |
Average Days of Receivables |
— | — | — | — | 0.00 | 0.00 | 0.84 | 34.24 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 160.75% | 114.42% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 46.51% | 29.42% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 23.97% | 15.25% |
Graham Net Nets |
— | — | — | — | — | — | 0.32 | 0.14 |
Graham Number |
— | — | — | — | — | — | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | (14.70%) | (2.93%) |
Free Cash Flow Yield |
— | — | — | — | — | — | 7.41% | (2.11%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.02 | 1.49 |
Operating CF per Share |
— | (0.14) | (15.20) | (2.37) | (1.96) | (0.85) | 0.57 | (0.27) |
Capex per Share |
— | 0.00 | (2.23) | (0.39) | (0.27) | (0.37) | (0.05) | (0.06) |
Free Cash Flow per Share |
— | (0.14) | (17.43) | (2.76) | (2.23) | (1.22) | 0.51 | (0.33) |
Cash per Share |
— | 0.21 | 27.49 | 13.84 | 5.59 | 4.52 | 5.04 | 4.54 |
Shareholders Equity per Share |
— | (0.28) | (32.12) | 13.90 | 5.75 | 3.49 | 3.02 | 2.81 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.28) | (32.12) | 13.90 | 5.75 | 3.49 | 3.02 | 2.81 |
Free Cash Flow |
— | (6.17) | (26.44) | (69.02) | (105.27) | (62.78) | 38.01 | (27.50) |
Working Capital |
— | 5.47 | 14.32 | 332.03 | 250.32 | 189.62 | 220.49 | 328.97 |
Capital Expenditures |
— | (1.38) | (3.39) | (9.65) | (12.80) | (18.98) | (3.99) | (4.70) |
Net Current Asset Value |
— | (13.48) | (54.51) | 329.85 | 204.91 | 111.71 | 161.64 | 177.58 |
EV/EBIT |
— | — | — | — | — | — | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.04 |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.05 | 0.12 | 0.17 | 0.14 | 0.18 | 0.28 | 0.32 |
Cash ROIC |
— | (38.47%) | 376.18% | (9.95%) | (19.67%) | (15.25%) | 6.39% | (4.51%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 223.07 | 21.01 |
Accounts Payable Turnover |
— | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 16,196.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | — | — | 4.08 | 0.34 | 5.89 |
Average Payables |
— | 5.13 | 5.13 | 6.81 | 7.21 | 9.51 | 14.18 | 10.38 |
Average Assets |
— | 5.55 | 30.24 | 207.85 | 354.36 | 323.07 | 371.24 | 443.70 |
Average Common Equity |
— | (30.44) | (30.44) | 149.39 | 309.46 | 225.33 | 201.09 | 228.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026